Geographic Area – Page 22

GSK Faces Major Setback in Zantac Litigation as Judge Allows Over 70,000 Lawsuits to Proceed

11 months ago talkbio0Tagged court, Delaware, Judge, Malignant Neoplasms, Medinilla, NDMA, ranitidine, SmithKline Beecham, Zantac

GSK, Zantac, Lawsuits, Cancer, Delaware Court, Judge Vivian Medinilla, Ranitidine, NDMA, Pharmaceuticals

Eli Lilly Invests $5.3 Billion in Indiana Plant to Boost Diabetes and Obesity Drug Production ###

11 months ago talkbio0Tagged alpha 1-antitrypsin, Diabetes, Eli, Eli Lilly, Glucagon-Like Peptide 1, Indiana, Manufacture, Mounjaro, Nordisk, Obesity, Zepbound

Eli Lilly, Diabetes, Obesity, Mounjaro, Zepbound, Tirzepatide, Indiana, Manufacturing, API, Novo Nordisk, GLP-1 drugs

FDA Approves Tris Pharma’s Onyda XR, First Liquid Non-Stimulant ADHD Medication for Pediatric Patients ###

11 months ago talkbio0Tagged Approved, Attention deficit hyperactivity disorder, clonidine, Extended Release Suspension, hydrochloride, Liquid medication, LiquiXR, Non-stimulant, Onyda, Pediatric brand name, Svalbard, Technology, Tris Pharma, United States Food and Drug Administration

Tris Pharma, Onyda XR, ADHD, Non-stimulant, Liquid medication, Pediatric patients, FDA approval, Clonidine hydrochloride, Extended-release oral suspension, LiquiXR technology

BioNTech Secures $145M from CEPI to Expand mRNA Vaccine Production in Africa

11 months ago talkbio0Tagged Africa, BioNTech, CEPI, equity, mRNA Vaccine, public health medicine (field), Vaccines

BioNTech, CEPI, mRNA vaccine production, Africa, vaccine equity, public health security

Asahi Kasei Acquires Calliditas Therapeutics for $1.1 Billion to Expand in Rare Disease Market

11 months ago talkbio0Tagged Acquisition (action), Asahi Kasei, Calliditas, IGA Glomerulonephritis, Kidney Diseases, Market, pharmaceutical growth strategy, Tarpeyo

Asahi Kasei, Calliditas Therapeutics, acquisition, rare disease market, kidney disease, Tarpeyo, IgA nephropathy, pharmaceutical growth strategy

Insmed’s Stocks Skyrocket Following Triumphant Phase III Results for Brensocatib in Bronchiectasis Treatment

11 months ago talkbio0Tagged Approved, brensocatib, Bronchiectasis, Insmed, Lung diseases, Market, New Drug Application, Phase 3 Clinical Trials, surge, United States Food and Drug Administration

Insmed, brensocatib, bronchiectasis, Phase III trial, lung disease, stock surge, New Drug Application, FDA approval, market value

Takeda Announces 641 Layoffs in Massachusetts Amid $900 Million Restructuring Campaign

11 months ago talkbio0Tagged Cambridge, Lexington, Massachusetts (geographic location), restructuring, Takeda

Takeda, layoffs, Massachusetts, restructuring, pharmaceuticals, biotech, Cambridge, Lexington

BioNTech Strengthens ADC Partnership with China’s MediLink, Investing $25M Upfront

11 months ago talkbio0Tagged Antibody-Drug Conjugates, BioNTech, biotech, China, Collaboration, Germany, MediLink, Solid Neoplasm, Technology Platform, TMALIN

BioNTech, MediLink Therapeutics, Antibody-Drug Conjugate (ADC), Solid Tumors, TMALIN ADC Platform, Biotech Collaboration, China, Germany

Innovent to Submit IL-23 Psoriasis Drug to Chinese Regulators Following Phase 3 Success

11 months ago talkbio0Tagged China, CLEAR-1, Clinical Research, Dental Plaque, Innovent, interleukin-23, picankibart, Psoriasis, regulatory

Innovent, IL-23, psoriasis, picankibart, phase 3, China, regulatory submission, plaque psoriasis, CLEAR-1 study

Minimal Weight Reduction Observed with Low Doses of New Zealand’s GLP-1/GLP-2 Agonist

11 months ago talkbio0Tagged Agonist, Body Weight, Dosage, Effect, GLP-1/GLP-2, Lowest, Minimal, New Zealand

New Zealand, GLP-1/GLP-2 agonist, weight reduction, lowest doses, minimal effect.